Johnson & Johnson's US net drug prices declined for the fourth consecutive year, down 5.7% on average across the portfolio, the company said in its annual drug pricing transparency report. Pointing to years of net price declines across the US drug portfolio, J&J used the platform to push for US drug price reforms that direct savings from rebates to patients rather than pharmacy benefit managers (PBMs).
The compound annual net price of the medicines sold under its Janssen drug unit has declined 14.4% since the beginning of 2016, the company said in a recent report, although...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
